Navigation Links
Cytomegalovirus exacerbates atherosclerosis through an autoimmune mechanism

A new study conducted by researchers from the University of Verona and the Institute G. Gaslini in Genova, Italy, confirms the pivotal role played by Cytomegalovirus infection in the pathogenesis of atherosclerosis.

Atherosclerosis is the main cause of morbidity and mortality worldwide. Classic risk factors including smoking, diabetes, hypertension and high cholesterol levels are known to play a pivotal role in the pathogenesis of the disease that also recognises a genetic influence. However, it is well known that acute cardiovascular events may happen without the presence of the mentioned common risk factors. Recently inflammation and infectious agents have been shown to play an important role in the onset of acute cardiovascular events.

The online, open-access PLoS ONE publishes a new study on the relationship between Cytomegalovirus infection and atherosclerosis, conducted by Prof. Roberto Corrocher and Claudio Lunardi from the University of Verona and by Prof. Antonio Puccetti from the Institute G. Gaslini in Genova, Italy.

The same researchers have already shown that Cytomegalovirus infection can be responsible of the initial vascular lesions typical of the atherosclerotic process. The mechanism involved in the vascular lesion is of autoimmune origin: antibodies directed against particular proteins of the virus are able to bind molecules expressed on the surface of the cells that line the arterial walls (endothelial cells) and to cause their death (apoptosis) through a mechanism called "molecular mimicry."

Using a biocomputational technique, the new study shows that the same anti-Cytomegalovirus antibodies, isolated from patients with coronary artery disease, are able to induce the activation not only of genes involved in apoptosis but also of many other genes that encode for proteins involved in different aspects of the atherosclerotic process (lipid metabolism, inflammation, adhesion molecules, etc.). For the first t ime, the study shows that one of these proteins is very important because of its ability to activate cells of the innate immune system involved in the initial phases of the disease.

This new study therefore confirms that antibodies directed against Cytomegalovirus-derived proteins purified from patients with coronary artery disease induce endothelial cells damage and support the hypothesis that virus infection plays a crucial role in mediating the atherosclerotic process. Moreover, these findings contribute to the design of novel preventive and therapeutic strategies.
'"/>

Source:Public Library of Science


Related biology news :

1. In mice, drug protects against diabetes and atherosclerosis
2. Termites feed through good vibrations
3. Recent breakthroughs in common adult leukemia highlighted in New England Journal of Medicine
4. Breakthrough Microarray-based Technology for the Study of Cancer
5. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
6. BRCA1 causes ovarian cancer through indirect, biochemical route
7. Breakthrough method in nanoparticle synthesis paves the way for new pharmaceutical and biomedical applications
8. Self-assembled nano-sized probes allow Penn researchers to see tumors through flesh and skin
9. HIV-1 spread through six transmission lines in the UK
10. MUHC researchers make cancer target breakthrough
11. Breakthrough isolating embryo-quality stem cells from blood

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology: